National Plan For Alzheimer’s And Dementia Gets An Update From HHS

TL;DR

For listenersOffer from Amazon

Turn your wind-down time into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

HHS announced an update to the National Plan to Address Alzheimer’s Disease and Related Dementias, replacing six historical goals with four focused on risk reduction, prevention and treatment, care, and caregiver support. Related initiatives include an ARPA-H-backed platform trial, an FDA prevention accelerator and expanded brain-health resources; their results and timelines are not yet clear.

HHS announced an update to the National Plan to Address Alzheimer’s Disease and Related Dementias on Thursday, setting out four goals centered on dementia risk reduction, prevention and treatment, care, and caregiver support. The announcement also outlined new federal research and prevention initiatives, including an ARPA-H-funded platform trial intended to test potential Alzheimer’s therapies.

The updated plan replaces six historical goals with four: promote dementia risk reduction across the lifespan; accelerate ways to prevent and treat Alzheimer’s and dementia; add dementia care components; and strengthen support for caregivers. HHS said the plan places greater emphasis on earlier detection and intervention.

Several initiatives accompany the revision. ARPA-H announced a collective investment of up to $48.8 million in projects. Up to $41 million is designated for Mass General Brigham researchers to lead a multi-institutional platform trial. The trial is intended to test drugs already approved for other conditions for possible use against Alzheimer’s, along with supplements, plant-derived products and other compounds. ARPA-H will also award $2.75 million to support University of California San Francisco research complementing existing work on sleep-related risks and early protein dysfunction.

The FDA also launched an Alzheimer’s Prevention Accelerator within its Neuroscience Advancement and Innovation Nexus program. HHS said the accelerator is intended to foster approaches to preventing or delaying Alzheimer’s-related cognitive decline. Separately, the Administration for Community Living plans to expand brain-health resources and training for elder-justice professionals, including lawyers and social workers who work to prevent abuse and financial exploitation of older adults.

Research, Prevention and Care

The update links federal research funding with a broader set of prevention, care and caregiver-support priorities. The platform trial could let researchers evaluate multiple kinds of potential interventions, including medicines developed for other conditions. That is a research plan, however, not evidence that any of the candidates prevent or treat Alzheimer’s.

The plan also addresses issues beyond drug development. HHS described work on dementia screening and training, behavioral-health and crisis-response resources for people with cognitive decline, public-health approaches, diagnostic delays, and dementia’s economic burden. A lifestyle intervention will also be tested among people with mild cognitive impairment. These efforts may shape what services and research receive federal attention, while their practical effect will depend on implementation, evidence and access.

The Alzheimer’s Association welcomed the administration’s focus on innovation and better care, but said advances matter only if people can access them. The group pointed to Medicare access to Alzheimer’s blood-based biomarker testing and urged Congress to pass the bipartisan Alzheimer’s Screening and Prevention Act. Its statement is an advocacy position, not a change to Medicare coverage announced in the HHS update.

Four Goals Replace Six

The National Plan to Address Alzheimer’s Disease and Related Dementias is the federal framework named in HHS’s announcement. The revised version reorganizes its priorities from six historical goals into four broader areas, with risk reduction and earlier intervention prominent in the new framing.

The announcement brings together activity across several agencies rather than describing a single research award. ARPA-H is funding research projects; the FDA accelerator is part of a new agency program; and the Administration for Community Living is expanding resources and training. HHS also listed evidence reviews on prevention and work to examine diagnostic delays and the financial burden of dementia. The source report did not provide completion dates or detailed budgets for every initiative.

“Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments.”

— HHS Secretary Robert F. Kennedy Jr., in an HHS news release

Trial Details and Access

The announcement does not specify when the platform trial will begin, how many participants it will enroll, which particular compounds will be tested, or how researchers will select them. It also does not report results: the proposed testing is a research initiative, and the compounds’ safety and effectiveness for Alzheimer’s remain to be established.

HHS’s account does not provide schedules, outcome measures or full funding details for the plan’s other initiatives. It is also unclear how the plan’s goals will be measured, when the FDA accelerator will produce projects or findings, and whether the expanded resources will change access to screening, treatment or caregiver services. The Alzheimer’s Association’s call for congressional action on Medicare biomarker testing is separate from the agency announcements.

Implementation and Research Milestones

Researchers and agencies will need to turn the announced priorities into specific projects, trial protocols, resources and timelines. For the ARPA-H platform trial, relevant next details include the candidate interventions, participating institutions, enrollment plans and the schedule for reporting findings. No results or trial start date were given in the source report.

Further developments may also clarify how the FDA accelerator will operate and what brain-health training the Administration for Community Living will provide. HHS said other work will address screening, dementia care, prevention evidence and the economic burden of the disease. Separately, whether Congress acts on the Alzheimer’s Association’s request concerning the ASAP Act remains a legislative question.

Key Questions

What changed in the national Alzheimer’s plan?

HHS replaced six historical goals with four, focused on dementia risk reduction, prevention and treatment, dementia care, and caregiver support.

What is the ARPA-H platform trial expected to test?

Mass General Brigham researchers are set to lead a multi-institutional trial using up to $41 million in ARPA-H funding. It is intended to test drugs approved for other conditions, as well as supplements, plant-derived products and other compounds, as potential Alzheimer’s interventions.

Have the therapies in the trial been shown to treat Alzheimer’s?

No results were reported in the announcement. The trial is intended to test possible therapies; the source does not establish that any candidate is effective for Alzheimer’s.

What does the FDA’s Alzheimer’s Prevention Accelerator do?

The FDA said the accelerator, part of its Neuroscience Advancement and Innovation Nexus program, is intended to foster approaches to prevent or delay cognitive decline due to Alzheimer’s. Specific projects and timelines were not provided in the report.

Does the update change Medicare coverage for blood tests?

The HHS announcement, as described in the source report, did not announce a Medicare coverage change. The Alzheimer’s Association urged Congress to pass the bipartisan ASAP Act and said access to blood-based biomarker testing matters.

Source: rss